Parabilis Medicines (NASDAQ: PBLS) jumped 58% in its first trading session on the Nasdaq Global Select Market this week, closing just above $31 per share. The clinical-stage biopharmaceutical firm raised $670 million in its base initial public offering, claiming the title of the biggest biotech IPO in history and surpassing the $604 million record set by Moderna in 2018.
The blockbuster listing caps a red-hot year for global IPO markets, where technology names have led the charge. Cerebras Systems has delivered the largest offering of 2026 so far, while SpaceX is on track to launch the biggest IPO ever. Anthropic and OpenAI have also filed confidentially with regulators in recent weeks, signaling their own public debuts may be imminent. Beyond tech, biotech has emerged as a second booming corner of the new-issue market. Kailera Therapeutics already broke Moderna’s long-standing fundraising record with its April IPO, and Parabilis has now lifted the industry bar higher just two months later.
Founded in 2015, Parabilis is built on years of research from Greg Verdine’s laboratory at Harvard University, with its proprietary Helicon platform forming its core competitive edge. The technology addresses one of the drug industry’s longest-standing challenges: so-called “undruggable” protein targets. Roughly 80% of validated disease targets fall into this category, as the proteins sit inside cells and lack the concave surfaces that conventional small molecules and antibodies require to bind and exert their effects. Verdine’s team engineered stabilized alpha-helix peptides capable of penetrating cells and binding to flat protein surfaces, breaking the boundaries of traditional drug development. Parabilis says Helicons are the only therapeutic modality in existence with both cell-entry and flat-surface binding capabilities.
The company is helmed by Chief Executive Officer Mathai Mammen, the former global head of research and development at Johnson & Johnson. During his tenure at the pharmaceutical giant, Mammen led teams that secured approvals for nine medicines spanning oncology, immunology and neuroscience, bringing deep expertise in clinical development and commercialization to the early-stage biotech.
Parabilis’ lead candidate, zolucatetide, is scheduled to begin a Phase 3 trial for desmoid tumors — noncancerous growths with very limited treatment options — in the first half of next year. The therapy has been studied in more than 150 patients to date, yielding what the company describes as promising results across multiple tumor types. Zolucatetide is also being evaluated in four Phase 1 studies, including trials for hepatocellular carcinoma and colorectal cancer. The biotech has a roster of additional candidates in preclinical development and aims to expand its technology platform into therapeutic areas beyond oncology over time.
Like most clinical-stage biotechs, Parabilis has seen its losses deepen as it ramps up research investment. The company posted a net loss of $145 million last year, with research and development expenses reaching $125 million. While that trajectory is typical for firms at this stage of growth, the ongoing need for capital adds significant investment risk. Proceeds from the IPO will be used to fund zolucatetide’s Phase 3 program, earlier-stage trials for other indications, and broader preclinical research.
Underwriters fully exercised their overallotment option following the offering, bringing total gross IPO proceeds to $770.5 million before deducting underwriting discounts, commissions and offering expenses, the company said in a subsequent announcement. Parabilis also closed a concurrent private placement of $75 million with Regeneron Pharmaceuticals, selling shares at $18 apiece, or 90% of the IPO price. Combined with other private financings and strategic collaborations this year, Parabilis has raised more than $1.2 billion in total funding in 2026.
Investor enthusiasm for the stock reflects the transformative potential of Parabilis’ platform, though market observers note it could take years for successful programs to translate into revenue. For risk-averse investors, the biotech may not be a suitable pick given its early-stage profile and post-IPO valuation jump. More aggressive investors with a multi-year holding horizon, meanwhile, may be better off waiting for a pullback rather than chasing the first-day surge.
